Regulatoriskt pressmeddelande

The Board of CellaVision AB appoints Steve Ferguson as CEO

The Board of Directors of CellaVision AB (publ) (“CellaVision” or the “Company”) has today appointed Steve Ferguson as the new Chief Executive Officer effective immediately. The Company’s current CEO, Simon Østergaard, will remain with CellaVision during a transition period to ensure a smooth handover.

Steve Ferguson holds a degree in Business from Queen’s University Belfast. Steve has over 25 years of experience in the biotechnology industry and most recently served as CEO of the biotechnology company Medix Biochemica, a position he held since 2020. Prior to that, Steve served as Vice President of European Operations at ThermoFisher Scientific’s ImmunoDiagnostics Division. Before his time at Thermo Fisher Scientific, Steve held various leadership positions at Lundbeck Ltd. The Board believes that now is the right time for new leadership that can guide CellaVision towards a clearer commercial focus, to drive a stronger growth agenda for the current portfolio and execute the commercialization of the innovation portfolio.

“Steve brings a strong commercial background. Over the coming years, CellaVision will maintain a heavy focus on launching and commercializing its exciting innovation portfolio, where strong commercial leadership is required to secure success. The Board would also like to extend its sincere thanks to Simon Østergaard for his significant contributions and strong commitment over the past five years to developing CellaVision during his tenure as CEO. Simon will remain with the company during a transition period to ensure a smooth handover.”, says CellaVision’s Chairman, Zlatko Rihter.

"I am deeply honoured to take over as CEO of CellaVision - a fantastic company with a strong product and innovation portfolio, and highly competent employees. Together, we will build upon the solid foundation in place and accelerate our growth journey in the global market," says CellaVision’s incoming Chief Executive Officer, Steve Ferguson.

Contact:
Zlatko Rihter
Chairman
Phone: + 46 733 621106
E-mail: zlatko.rihter@hotmail.com
www.cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company’s 13 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com